2024
Severity of Respiratory Syncytial Virus vs COVID-19 and Influenza Among Hospitalized US Adults
Surie D, Yuengling K, DeCuir J, Zhu Y, Lauring A, Gaglani M, Ghamande S, Peltan I, Brown S, Ginde A, Martinez A, Mohr N, Gibbs K, Hager D, Ali H, Prekker M, Gong M, Mohamed A, Johnson N, Srinivasan V, Steingrub J, Leis A, Khan A, Hough C, Bender W, Duggal A, Bendall E, Wilson J, Qadir N, Chang S, Mallow C, Kwon J, Exline M, Shapiro N, Columbus C, Vaughn I, Ramesh M, Mosier J, Safdar B, Casey J, Talbot H, Rice T, Halasa N, Chappell J, Grijalva C, Baughman A, Womack K, Swan S, Johnson C, Lwin C, Lewis N, Ellington S, McMorrow M, Martin E, Self W. Severity of Respiratory Syncytial Virus vs COVID-19 and Influenza Among Hospitalized US Adults. JAMA Network Open 2024, 7: e244954. PMID: 38573635, PMCID: PMC11192181, DOI: 10.1001/jamanetworkopen.2024.4954.Peer-Reviewed Original ResearchConceptsInvasive mechanical ventilationRespiratory syncytial virusSeverity of RSV diseaseInfluenza diseaseVaccinated patientsIn-hospital deathUnvaccinated patientsRSV diseaseSyncytial virusClinical decision-makingComposite of invasive mechanical ventilationOutcome of invasive mechanical ventilationSeverity of respiratory syncytial virusLaboratory-confirmed respiratory syncytial virusHospitalized US adultsInfluenza vaccination statusVaccination statusAcute respiratory illnessMultivariate logistic regressionCenters for Disease Control and PreventionSeverity of COVID-19Disease Control and PreventionInfluenza infectionInfluenza severityClinical outcomesInterim Estimates of 2023–24 Seasonal Influenza Vaccine Effectiveness — United States
Frutos A, Price A, Harker E, Reeves E, Ahmad H, Murugan V, Martin E, House S, Saade E, Zimmerman R, Gaglani M, Wernli K, Walter E, Michaels M, Staat M, Weinberg G, Selvarangan R, Boom J, Klein E, Halasa N, Ginde A, Gibbs K, Zhu Y, Self W, Tartof S, Klein N, Dascomb K, DeSilva M, Weber Z, Yang D, Ball S, Surie D, DeCuir J, Dawood F, Moline H, Toepfer A, Clopper B, Link-Gelles R, Payne A, Chung J, Flannery B, Lewis N, Olson S, Adams K, Tenforde M, Garg S, Grohskopf L, Reed C, Ellington S, Collaborators C, Collaborators C, Lauring A, Arndorfer J, Bride D, Peltan I, Mohr N, Hager D, Prekker M, Mohamed A, Johnson N, Steingrub J, Khan A, Busse L, Duggal A, Wilson J, Qadir N, Mallow C, Kwon J, Exline M, Shapiro N, Columbus C, Vaughan I, Mosier J, Safdar B, Harris E, Chappell J, Stewart L, Swan S, Piedra P, Sahni L, Englund J, Zerr D, Hickey R, Williams J, Rohlfs C, Schlaudecker E, Dosdos D, Moffatt M, Schuster J, Weltmer K, Szilagyi P, Curley T, Mills J, Faryar K, Salata R, Geffel K, Nowalk M, Murthy K, Rose S, Smith M, Wickersham B, Williamson B, Bontrager N, Williams O, Kramer J, Nordstrom L, Monto A, Vaughn I, Dickerson M, McLean C, Noble E, Ray C, Sumner K, Essien I, Fletcher L, Heaton P, Kane S, McEvoy C, Thapa S, Vazquez-Benitez G, Bezi C, Contreras R, Davis G, Lewin B, Mahale P, Patrick R, Qian L, Rayens E, Reyes I, Ryan D, Salas S, Sy L, Yeh M, Zeng X, Fireman B, Goddard K, Hansen J, Jacobson K, Timbol J, Zerbo O, Dunne M, Zhuang Y. Interim Estimates of 2023–24 Seasonal Influenza Vaccine Effectiveness — United States. MMWR Morbidity And Mortality Weekly Report 2024, 73: 168-174. PMID: 38421935, PMCID: PMC10907036, DOI: 10.15585/mmwr.mm7308a3.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultCase-Control StudiesChildHumansInfluenza VaccinesInfluenza, HumanSeasonsVaccine EfficacyConceptsVaccine effectivenessInfluenza vaccineInfluenza virus infectionInfluenza-associated hospitalizationsAnnual influenza vaccinationSeasonal influenza vaccineTest-negative case-control study designCase-control study designOutpatient visitsInfluenza VEInfluenza BInfluenza seasonInfluenza APediatric patientsInfluenzaVirus infectionOutpatient settingMonthsVaccinePatientsStudy designHospitalAdultsVisitsUnited States
2023
Disease Severity of Respiratory Syncytial Virus Compared with COVID-19 and Influenza Among Hospitalized Adults Aged ≥60 Years — IVY Network, 20 U.S. States, February 2022–May 2023
Surie D, Yuengling K, DeCuir J, Zhu Y, Gaglani M, Ginde A, Talbot H, Casey J, Mohr N, Ghamande S, Gibbs K, Files D, Hager D, Ali H, Prekker M, Gong M, Mohamed A, Johnson N, Steingrub J, Peltan I, Brown S, Leis A, Khan A, Hough C, Bender W, Duggal A, Wilson J, Qadir N, Chang S, Mallow C, Kwon J, Exline M, Lauring A, Shapiro N, Columbus C, Vaughn I, Ramesh M, Safdar B, Halasa N, Chappell J, Grijalva C, Baughman A, Rice T, Womack K, Han J, Swan S, Mukherjee I, Lewis N, Ellington S, McMorrow M, Martin E, Self W, Network I. Disease Severity of Respiratory Syncytial Virus Compared with COVID-19 and Influenza Among Hospitalized Adults Aged ≥60 Years — IVY Network, 20 U.S. States, February 2022–May 2023. MMWR Morbidity And Mortality Weekly Report 2023, 72: 1083-1088. PMID: 37796753, PMCID: PMC10564326, DOI: 10.15585/mmwr.mm7240a2.Peer-Reviewed Original ResearchConceptsHigh-flow nasal cannulaInvasive mechanical ventilationRSV disease severityNoninvasive ventilationDisease severityCOVID-19Intensive care unit admissionRespiratory syncytial virus vaccinationOlder adultsLaboratory-confirmed RSVCare unit admissionAcute respiratory illnessFlow oxygen therapyMultivariable logistic regressionCDC's Advisory CommitteeRespiratory syncytial virusSARS-CoV-2Advisory CommitteeUnit admissionICU admissionImmunization PracticesRSV vaccinationVirus vaccinationAdults AgedInfluenza severity